A: Chemical structure of pterosin A

Slides:

Advertisements

Similar presentations

Effects of senescent cells on activity.

Advertisements

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.

Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. Development of stable STZ-induced diabetes requires.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Exosomes transfected with obesity-associated miRNAs induce glucose intolerance dissociated from obesity. Exosomes transfected with obesity-associated miRNAs.

A: Total collagen content by Sirius red staining in cardiac tissue of control (SD) animals. A: Total collagen content by Sirius red staining in cardiac.

BTG2 regulates gluconeogenic gene expression in diabetic mouse models

Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A:

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

A and B: Total caloric intake in sham rats on chow and in gastroduodenal and hepatic vagotomized rats treated with STZ with access to lard and chow. A.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.

Liver AMPK is activated by oral administration of canagliflozin in mice, but this does not explain changes in RER. A: Phosphorylation of AMPK, ACC, and.

Activation of β-adrenoceptors improves glucose tolerance in diabetic animals and increases glucose uptake in vivo, ex vivo, and in vitro. Activation of.

Effect of the acute administration of benzylamine plus vanadate on oral glucose tolerance test in STZ-induced diabetic rats. Effect of the acute administration.

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

FGF21 signaling in hypothalamus is blocked by FGFR1 neutralizing antibody. FGF21 signaling in hypothalamus is blocked by FGFR1 neutralizing antibody. Twelve-week-old.

PMPs survive STZ cytotoxicity and produce larger colonies with a higher yield of insulin+ progeny. PMPs survive STZ cytotoxicity and produce larger colonies.

Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice. Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice.

Appearance of insulin in plasma and CSF at different times after the administration of subcutaneous DET and GLAR in mice and the effect of chronic DET.

Sustained activation of AMPK α2 in muscle of subjects with type 2 diabetes after an overnight withdrawal of metformin. Sustained activation of AMPK α2.

Glucose tolerance in WT and TRPM2-KO mice.

ΑGLP-1R−/− mice show glucose intolerance and disturbed glucagon secretion in response to i.p. glucose administration. αGLP-1R−/− mice show glucose intolerance.

Effects of the β-cell–specific expression of mKL on blood glucose levels, glucose tolerance, insulin sensitivity, and plasma insulin levels in STZ-induced.

HFHC/STZ guinea pigs develop insulin-independent diabetes that is responsive to oral antihyperglycemic therapy. HFHC/STZ guinea pigs develop insulin-independent.

Effects of pterosin A on serum levels of lipid, blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT)

The effect of VSG on body weight and body fat in GLP-1r KO mice.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

Chop deletion preserves β-cell function in P58IPK−/− mice.

Rapid improvement of glucose tolerance induced by PP

Adoptive transfer of purified activated G9Cα−/−

Effect of PEDF+DHA treatment on wound healing in diabetic corneas.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

GLP-1 and gastrin combination therapy induces immunoregulatory cell activity in NOD mice. GLP-1 and gastrin combination therapy induces immunoregulatory.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

HFD feeding induced insulin resistance in TRIB3 MOE mice.

High-glucose–induced insulin resistance in TRIB3 MOE mice.

Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic steatosis. Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic.

Insulin resistance and hepatic steatosis in ASKO mice.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Effects of Rosi treatment on ASKO mice.

Effects of chow-diet feeding on control and TRIB3 MOE mice.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

High-fat diet–induced glucose intolerance is prevented in ghrelin knockout (Ghr-KO) mice. High-fat diet–induced glucose intolerance is prevented in ghrelin.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Blood glucose levels in chicken embryos.

Mice lacking Y1 receptor in the hematopoietic compartment remain healthy under normal chow feeding conditions. Mice lacking Y1 receptor in the hematopoietic.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Glycemic control and body weight over 52 weeks.

Cytokine changes in LPS-induced TNFα and spontaneous IL-6 production in whole-blood cultures. Cytokine changes in LPS-induced TNFα and spontaneous IL-6.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

5FU-induced specific activation of CD8+ T cells.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

PDL192 and inhibit the growth of xenograft tumors.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Presentation transcript:

A: Chemical structure of pterosin A A: Chemical structure of pterosin A. Effects of pterosin A on hyperglycemia, glucose intolerance, and body weight in a STZ-induced diabetic mouse (DM) model. A: Chemical structure of pterosin A. Effects of pterosin A on hyperglycemia, glucose intolerance, and body weight in a STZ-induced diabetic mouse (DM) model. The STZ-induced diabetic mice were orally treated with pterosin A (10–100 mg/kg) for 4 weeks, and the oral glucose tolerance test was performed (B) and the body weights were measured (C). D: Mice were pretreated with pterosin A for 3 days, STZ was injected, and the oral glucose tolerance test was performed after 1 week. Data are presented as mean ± SEM (n = 8). *P < 0.05 vs. diabetic mice without pterosin A; #P < 0.05 vs. diabetic mice alone. Feng-Lin Hsu et al. Diabetes 2013;62:628-638 ©2013 by American Diabetes Association